How We Work Together
Every project starts with a free 30-minute call to understand your data, your questions, and your timeline. From there, we will scope a project that fits.
Focused Analysis
Starting at $3,500
1-2 weeks
Ideal for
- Single-dataset analysis (scRNA-seq, flow cytometry, bulk RNA-seq)
- Publication-ready figures from existing data
- Statistical analysis for a manuscript revision
- Quick QC and exploratory analysis
You get
- Analysis report with figures
- Documented code and scripts
- 30-minute results walkthrough
Full Pipeline
Starting at $8,000
3-6 weeks
Ideal for
- End-to-end scRNA-seq or multi-omic pipeline builds
- ML model development for your biological data
- Rebuilding a fragile or undocumented pipeline
- Multi-dataset integration and comparative analysis
You get
- Everything in Focused Analysis
- Reproducible, version-controlled pipeline
- Full documentation and handoff
- Two rounds of revision
Ongoing Partnership
Starting at $3,000/mo
Monthly retainer
Ideal for
- Biotech startups without in-house bioinformatics
- Labs with ongoing data generation
- Multi-experiment studies needing consistent analysis
- Grant-funded projects needing computational support
You get
- Dedicated hours each month (typically 15-25 hrs)
- Priority turnaround on requests
- Slack or Teams access for async communication
- Monthly strategy calls
Not sure which tier fits? That is exactly what the 30-minute call is for. No pitch, no pressure, just a conversation about your data and what you need.
Common Questions
What if my project doesn't fit neatly into a tier?
Most don't, and that's fine. These are starting points. We'll scope a custom proposal based on your specific data and questions after our initial call.
Do you work with confidential or proprietary data?
Yes. We sign NDAs as standard practice and can work within your institution's data governance requirements. All data is handled on secure, encrypted infrastructure.
Can you be listed as a contributor on publications?
If the analytical contribution warrants it under ICMJE guidelines, absolutely. We can discuss authorship expectations upfront.
I'm a startup. Do you offer equity-based arrangements?
We're open to hybrid cash and equity structures for the right early-stage companies. Let's discuss during the call.
Ready to scope your project?
Book a free 30-minute call and we will figure out the best path forward for your data.
Book a Free 30-Minute Call